All In Biotech

Drug Trial Radar · NCT05650385

A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

A Multicenter, Open-label, Dose-escalating Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

68

Planned (sponsor's estimate)

Start

Dec 2022

Primary completion

Dec 2023

Study completion Oct 2025

Sponsor

Sponsor type
Industry
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to characterize the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of B1962, a PD-L1/VEGF bispecific antibody fusion protein, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of two parts: a once-weekly (QW) dosing phase and a biweekly (Q2W) dosing phase, which will explore the possibility of Q2W dosing of B1962 based on the PK data obtained in the QW phase. The study will determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for B1962 as a single agent.

Conditions

  • Neoplasms Malignant

Interventions

  • B1962Drug

    B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT AssessmentTime frame: From Day1 to Day15 after first dose of B1962
  2. AE AssessmentTime frame: From first dose of B1962 until 28 days after the last dose of B1962.
  3. 12-lead ECG AssessmentTime frame: From first dose of B1962 until 28 days after the last dose of B1962.
  4. Eastern Cooperative Oncology Group score AssessmentTime frame: From first dose of B1962 until 28 days after the last dose of B1962.
  5. Determine the maximum tolerated dose (MTD)Time frame: From first dose of B1962 until 28 days after the last dose of B1962
  6. Determine the recommended phase II dose (RP2D)Time frame: From first dose of B1962 until 28 days after the last dose of B1962

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.